share_log

China Meheco Group (SHSE:600056) Investors Are Sitting on a Loss of 20% If They Invested a Year Ago

China Meheco Group (SHSE:600056) Investors Are Sitting on a Loss of 20% If They Invested a Year Ago

中國Meheco集團(上海證券交易所股票代碼:600056)如果投資者在一年前進行投資,他們將蒙受20%的損失
Simply Wall St ·  05/27 03:21

It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by China Meheco Group Co., Ltd. (SHSE:600056) shareholders over the last year, as the share price declined 21%. That's well below the market decline of 10%. On the other hand, the stock is actually up 17% over three years.

購買指數基金可以輕鬆匹配整體市場回報。 雖然個別股票可能會贏得大贏家,但更多的股票無法產生令人滿意的回報。 在過去一年中,中國醫藥股份有限公司(SHSE:600056)股東們就實現了這一下行風險,股價下跌了21%,遠低於市場下跌的10%。 另一方面,股票實際上上漲了17%,而且是在過去三年內。上漲6.3%的三年中,股票的價格似乎沒有反映出EPS的增長。所以,有理由對一些其他指標進行研究。在不幸的12個月期間,其中中國醫藥的股價下跌,它的每股收益(EPS)實際上提高了22%。 過去的增長預期可能過於不合理。 鑑於收益率相當低,只有1.9%,我們對分紅在闡明股價方面的作用表示懷疑。 相反,收入下降了16%是一個真正的問題。 許多投資者認爲,收入下降很可能是降低收益的先驅,因此這可能很好地解釋了股價的疲軟。

So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.

那麼我們來看看這家公司的長期表現是否符合其業務進展情況。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

雖然有效市場假說仍然被一些人教授,但被證明市場是過度反應的動態系統,投資者並不總是理性的。檢查市場情緒如何隨時間變化的一種方法是看一個公司的股價與其每股收益(EPS)之間的交互作用。

During the unfortunate twelve months during which the China Meheco Group share price fell, it actually saw its earnings per share (EPS) improve by 22%. It's quite possible that growth expectations may have been unreasonable in the past.

鑑於CEO的薪酬少於類似公司的中位數,這可能值得注意。 但是,雖然CEO薪酬始終值得檢查,但真正重要的問題是該公司能否在未來增長收益。 如果您想進一步調查股票,可以從中國醫藥的收益,收入和現金流的這份自由互動報告開始。

It's fair to say that the share price does not seem to be reflecting the EPS growth. So it's well worth checking out some other metrics, too.

公允地說,股價似乎並未反映出每股收益的增長。因此,值得檢查一些其他指標。

Given the yield is quite low, at 1.9%, we doubt the dividend can shed much light on the share price. In contrast, the 16% drop in revenue is a real concern. Many investors see falling revenue as a likely precursor to lower earnings, so this could well explain the weak share price.

我們遺憾地報告,中國醫藥的股東們在今年下跌了20%(包括分紅)。 不幸的是,這比更廣泛的市場下跌的10%更糟。 話雖如此,不可避免地會有一些股票在下跌的市場中被過度拋售。 關鍵是注意基本面發展。 長期投資者不會那麼沮喪,因爲在五年內,他們每年可以獲得4%的回報。 如果基礎數據繼續表明長期可持續增長,當前的拋售可能是值得考慮的機會。 雖然值得考慮市場條件對股價的不同影響,但還有其他更重要的因素。 例如,我們發現了3個關於中國醫藥的警告信號(其中1個可能很嚴重!)在此投資之前,您應該意識到這些。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。

earnings-and-revenue-growth
SHSE:600056 Earnings and Revenue Growth May 27th 2024
SHSE:600056收益和營業收入增長2024年5月27日

It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. This free interactive report on China Meheco Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

這可能值得注意的是,CEO的薪酬低於類似規模公司的中位數。 但是,儘管CEO的薪酬始終值得檢查,但真正重要的問題是該公司能否在未來實現收益增長。 如果您想進一步調查該股,本免費互動報告可以從中國醫藥的收益,收入和現金流開始,這是一個很好的起點。

A Different Perspective

不同的觀點

We regret to report that China Meheco Group shareholders are down 20% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 10%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 4%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 3 warning signs for China Meheco Group (1 is potentially serious!) that you should be aware of before investing here.

很遺憾地通報,中國醫藥股東今年損失了20%(包括紅利)。不幸的是,這比整個市場下跌的10%更糟糕。 話雖如此,在下跌的市場中,一些股票被超賣是不可避免的。關鍵是要關注基本情況的發展。 長期投資者不會如此沮喪,因爲他們每年在五年內都能獲得4%的回報。 如果基本數據繼續表明長期可持續增長,則目前的拋售可能值得考慮。 雖然考慮市場條件對股價可能產生的不同影響非常有價值,但還有其他更重要的因素。 例如,我們發現了三個中國醫藥的警示信號(其中一個可能非常嚴重!)在投資之前,您應該意識到這些情況。

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找獲勝投資的人來說,最近有內部購買的低估公司免費列表可能是一個很好的選擇。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論